Trial Profile
A retrospective study investigating efficacy and safety outcomes of palivizumab prophylaxis in preventing respiratory syncytial virus infection in children with cystic fibrosis in Northern Ireland
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Feb 2017
Price :
$35
*
At a glance
- Drugs Palivizumab (Primary)
- Indications Respiratory syncytial virus infections
- Focus Therapeutic Use
- 24 Feb 2017 New trial record